Shire proposes $30 bln all-share tie-up with Baxalta

LONDON, Aug 4 (Reuters) - London-listed pharmaceutical group Shire said it was seeking to buy U.S. firm Baxalta in a $30 billion all-share deal to create a global specialist in medicines treating rare diseases with sales of $20 billion by 2020.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.